MARKSANS PHARMA LIMITED

Regd. Office: 11th Floor Lotus Business Park.Off. New Link Road. Andheri [West]. Mumbai-400053

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2013

PART 1

ExtraCULAGE   CANONICO   CANONI			l	3 MONTHS ENDED		6 MONTHS		ended rear
up- Net Coperating Income from Operations (Net of excise duhy) 19,135.40 (14,103.11 10,555.24 30,238.51 20,018.88 17.76 (14) (15) (14) (15) (15) (15) (15) (15) (15) (15) (15	Sr. No		(UNAUDITED)	30.06.2013 (UNAUDITED)	(UNAUDITED)	30.9.2013 (UNAUDITED)	(UNAUDITED)	31.03.2013 (AUDITED)
bs. Detail income from Operations (Net of acuties duly) 16.134.0 19. Chall income from Operations (Net of acuties duly) 16.34.0 19. Chall income from Operations (Net of acuties duly) 16.34.0 19. Chall income from Operations (Net of acuties duly) 19. Chall income from Operations (Net of acuties duly) 19. Chall income from Operations (Net of acuties duly) 19. Chall income from Operations (Net of acuties duly) 19. Chall income from Operations (Net of acuties duly) 19. Chall income (Ne	1	<b>D</b> 00						
Excellence   Trickal Income Principal Content   Trickal Income   Trickal			16,135.40 2.45	14,103.11 272.17	10,552.64	30,238.51	20,016.86	43,842.24
a) Coat Mannini Consumed b) Continuent b) Purchase of Stock - In- trade c) Purchase of Stock - In- trade c) Changes in Inventions of Ministed poods, work-in- programs and stock in- trade c) Changes in Inventions of Ministed poods, work-in- programs and stock in- trade c) Changes in Inventions of Ministed poods, work-in- programs and stock in- trade c) Changes in Inventions of Ministed Changes c) Chang		Total Income from operations (net)	16.137.85	14,375.28	10,918.05	30,513,13	20,454,37	44,281,78
a) Coast of Meninal Consumed         5,970,399         A,313,80         3,803,40         10,194,28         6,863,08           b) Purchase of Stock - In- Irade         3,970,399         4,313,80         3,803,40         10,194,28         6,863,08           b) Changes in Inventrotes of Initiated poods, work-in-propries and stock - Irade         1,652,79         1,557,79         0,320         110,59         (2,81)           of Changes in Inventrotes of Initiated poods of Englands and Contract Tracks         2,048,20         1,553,41         1,350,20         1,300,20         3,371,41         2,579,80           Of Charle Income         1,058,21         1,553,41         1,350,20         1,350,20         3,371,41         2,579,80           Of Charle Income         1,078,60         1,553,41         1,350,20         1,273,80         3,371,41         2,579,80           Of Charle Income         1,078,60         1,553,41         1,558,61         1,558,61         1,559,51         1,559,51         1,559,51         1,559,51         1,559,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52         1,579,52		2 Expenses						
Dispurational of Slock - In- trade   3,985   3,421,11   2,94,05   6,20,02   4,761,48		a) Cost of Material Consumed	5,870.39	4,313.89	3,630.40	10,184.28	6,650.86	13,592.88
Cyclusings in International Park		b) Purchase of Stock - in- trade	3,399.51	3,421.11	2,364.05	6,820.62	4,767.48	10,478.1
Employee brends expenses   1,853.41   1,586.01   1,350.20   3,371.41   2,3776   0) Chrys regenses   3,750   1,275.61   1,275.71   1,255.77		c) Changes in inventories of initiated goods , work-in- progress and stock- in- trade	(45.23)	155.79	(0.32)	110.56	(2.81).	1.215.4
Other expenses   2,044.27   1,727.81   1,477.80   3,814.31   3,915.12   1,727.80   3,915.12   1,727.80   3,915.12   1,727.80   1,127.80   3,915.12   1,278.80   1,127.80   3,915.12   1,278.80   1,127.80   3,915.12   1,278.80   1,127.80   3,915.12   1,278.80   1,127.80   3,915.12   1,278.80   1,127.80   3,915.12   1,278.80   1,127.80   3,915.12   1,278.80   1,287.80   1,2		d) Employee benefits expense	1,853.41	1,518.01	1,350.29	3,371.41	2,579.60	5,591.25
1,00 Cher expenses   1,00 Ch		e) Depreciation and amortisation expense	317.50	320.54	498.77	638.04	751.52	1,564.99
1,348.509 mon Oberations before other income, (1-2) 2,648.05   2,858.33   1,801.05   5,508.39   522.56   Chiral Income   2,648.05   2,848.64   1,998.19   1,459.77   4,247.85   (178.16)   Chiral Income   2,648.05   2,848.64   1,998.19   1,459.77   4,247.85   (178.16)   Chiral Income   2,648.05   2,848.64   1,998.19   1,459.77   4,247.85   (178.16)   Chiral Income   2,648.05   2,648.64   1,998.19   1,459.77   4,247.85   (178.16)   Chiral Income   2,648.05   2,648.64   1,998.19   1,459.77   4,247.85   (178.16)   Chiral Income   2,648.05   2,648.05   2,648.64   1,998.19   1,459.77   4,247.85   (178.16)   Chiral Income   2,648.05		f) Other expenses	2,094.22	1,787.61	1,273.80	3,881.83	5,185.16	6,024.71
Combes   Incomment   Combes			13,489.80	11,516.95	9,116.99	25,006.74	19,931.81	38,467.41
Combar Income	,		2.648.05	2.858.33	1.801.06	5,506,39	522.56	5.814.37
and exceptional items(3+4) (2,948 pt 1,989,15 pt 1,459,77 pt 1,258,54 pt 1,259,38 pt 1,901,06 pt 1,259,38 pt 1,901,06 pt 1,259,38 pt 1,901,06 pt 1,259,38 pt 1,259		_	-	•		,		
Finance cost) from rodinary activities after finance costs but 2,248,54 (1987) (1987) (1987) (1988) from rodinary activities after finance costs but 2,248,54 (1989) (1987	<b>,</b>		3 8 48 08	) pr pr	301.06	7 706 30	500 F6	# D
before exceptional returns(2-6) in both exceptional items (2-6) before exceptional items (2-6) before exceptional items (2-6) (2-86.4) (2-86.4) (1-898.19 (1-89.77 (1-89.16) (1-87.77 (1-87.77 (1-89.16) (1-87.77 (1			399.41	859.14	341.29	1,258.54	700.72	1,459.64
Exceptional limits   1,200		Profit/(Loss) from ordinary activities after finance costs but	2 248 64	1 909 19	1 450 77	4 247 BE	(179 16)	4 25 4 7
Prodrigit_Cass) from Ordinary activities before Tax (F-9)		B Exceptional items	1,1	.,000.10	., .		-	,,00,,,0
Tax Expenses (Includes Deferred Tax 8 Tax for Earler Year)         278 278         278 29         278 29           Net Profit/Loss) from Ordinary activities affer tax(9-10)         2,083.13         195.41         1,459.77         396.56         (178.16)           Loss: Extraordinary Item         Age of Profit/Loss) from Ordinary Items         2,063.13         1,916.41         1,459.77         396.56         (178.16)           Mat Profit/ (Loss) for Bascolated Social Soci		Profit/(Loss) from Ordinary activities before Tax (7-8)	2,248.64	1,999.19	1,459.77	4,247.85	(178.16)	4,354.73
Lest: Extracribles   1011	÷ =	1 Not Broffill ces from Ordinary activities after tay(9.10)	195.51	1 916 41	1 450 77	3 060 56	(178 16)	(527.89)
Nate Profit (Loss) for the period (11-12)         2,063.13         1,916.41         1,456.77         3,969.56         (178.19)           Share of Profit/(Loss) disasociaties         52.06         38.10         57.28         90.18         127.01           Minorly Inderest and Stare of Minorly Inderest and Stare of Minorly Inderest and Stare of Stare (Loss) after taxes, minority interest and share of associaties (13.14.15)         2,001.07         1,878.31         1,402.49         3,878.40         127.01           Read up Equity Share Capital (Face Value Re.1 each)         3,853.07         3,853.07         3,678.07         3,678.07         3,853.07         3		2 Less: Extraordinary Item	2,000.10	1,010.71	1,700.11	0,000.00		4,002.0
Share of Promit/(Loss) after taxes, minority interest and share of sasociates (13-14-15) associates (13-14-1		Net Profit/ (Loss) for the period (11-12)	2,053.13	1,916.41	1,459.77	3,969.56	(178.16)	4,882.62
Net Profit/(Loss) after taxes, minority interest and share of associates (13-14-15)         2,001.07         1,878.31         1,402.49         3,878.40         (305.17)           Past up Equity Share Capital (Face Value Re.1 each)         3,883.07         3,883.07         3,878.07         3,883.07         3,883.07         3,878.07         3,883.07         3,883.07         3,883.07         3,883.07         3,883.07         3,883.07			52.06	38.10	57.28	90.16	127.01	294 19
Paid up Equily Share Capital (Face Value Re.1 each)   3,833.07	10	Net Profit/(Loss) after taxes,minority interest and share of	2.001.07	1 878 31	1.402.49	3 879 40	(305 17)	4 588 4
Reservic Excluding Revaluation Reserve as per   Balanca Sheet of Previous Accounting year   1.03   (0.05)   1.03   (0.05)   2.05   0.40   0.38   1.01   (0.05)   0.05		7 Paid up Equity Share Capital (Face Value Re.1 each)	3,853.07	3,853.07	3,678.07	3,853.07	3,678.07	3,853.07
a) Earnings Per Share (before extraordinary items.Rs.)- Basic Diluted 0.53 0.50 0.40 0.38 1.03 (0.05) Diluted 0.52 0.49 0.38 1.01 (0.05) 0.52 0.49 0.38 1.01 (0.05) 0.52 0.49 0.38 1.01 (0.05) 0.52 0.49 0.38 1.01 (0.05) 0.52 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.05) 0.49 0.38 1.01 (0.08) 0.49 0.49 0.38 1.01 (0.08) 0.49 0.49 0.38 1.01 (0.08) 0.49 0.49 0.38 1.01 (0.08) 0.49 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.38 1.01 (0.08) 0.49 0.49 0.49 0.49 0.49 0.49 0.49 0.49	=	8 Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year						3,444.8
b) Earnings Per Share(effer extraordinary items- Rs.) - Basic Diluted 0.52 0.49 0.38 1.01 (0.08)    PARTICULARS OF SHAREHOLDING	1	9 a) Earnings Per Share (before extraordinary items.Rs.)- Basic   Diluted	0.53 0.53	0.50	0.40 0.38	1.03 1.03	(0.05) (0.05)	1.27 1.27
PARTICULLARS OF SHAREHOLDING         187,815,471         187,999,472         189,824,114         187,815,471         187,815,471         187,815,471         187,8			0.52 0.52	0.49 0.49	0.38 0.36	1.01 1.01	(0.08) (0.08)	1.19 1.19
Public Shareholding:	PART			•				
187,815,471 187,999,472 189,824,114 187,815,471 189,824,114 48.75% 51.61% 48.75% 51.61% 48.75% 51.61% 48.75% 51.61% 48.75% 51.61% 48.75% 51.61% 51.61% 48.75% 51.61% 51.61% 51.61% 51.61% 51.61% 51.61% 51.61% 51.61% 51.61% 51.61% 51.61% 51.61% 51.61% 51.25% 51.21% 48.39% 51.25% 48.39% 51.25% 48.39%					. ,			
48.75%         48.79%         51.61%         48.75%         51.61%           197,491,733         197,307,732         177,983,090         197,491,733         177,983,090           NIL         NIL         NIL         NIL         NIL         NIL         NIL           N.A         N.A         N.A         N.A         N.A         N.A         N.A           Mpany)         197,491,733         197,307,732         177,983,090         197,491,733         177,983,090           197,491,733         197,307,732         177,983,090         197,491,733         177,983,090           100%         100%         100%         100%         100%           48.39%         51.25%         48.39%         51.25%         48.39%		- Number of Shares	187,815,471	187,999,472	189,824,114	187,815,471	189,824,114	
NIL		- Percentage of Holding	48.75%	48.79%	51.61%	48.75%	51.61%	48.96%
NIL		a). Pledged/Encumbered	101,701,100	101,001,102	111,000,000	101,701,100	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	190,072,90
ter and N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A		- Number of Shares	NIL	NiL	N.	NIC.	Z.	NI-
N.A		- Percentage of Holding	N.A	N.A	Z.A	Z A	Z	Z
loiding N.A N.A N.A N.A Lal share capital of the Company)  197,491,733 197,307,732 177,983,090 197,491,733 177,983,090 10ding 100% 100% 100% 100% 100% 100% 100% 100		(as a % or the total snareholding of Promoter and Promoter Group)			•	••••		
es 197,491,733 197,307,732 177,983,090 197,491,733 177,983,090 10ding 100% 100% 100% 100% 100% 100% 100% 100		- Percentage of Holding	N.A	A'N	A.N	N.A	N.A	N.A
es 197,491,733 197,307,732 177,983,090 197,491,733 177,983,090 loiding 100% 100% 100% 100% 100% 100% 100% 100	Ī	b) Non-encumbered						
100%     100%     100%     100%       51.25%     51.21%     48.39%     51.25%     48.39%		- Number of Shares	197,491,733	197,307,732	177,983,090	197,491,733	177,983,090	١
51.25% 51.21% 48.39% 51.25%		- Percentage of Holding	100%	100%	100%	100%	100%	100%
51.25% 51.21% 48.39% 51.25%		(as a % of the total shareholding of Promoter and Promoter Group)						
( 0) -6 th- 1-1-1 -6 th- 0		- Percentage of Holding	51.25%	51.21%	48.39%	51.25%	48.39%	51.04%



	7,851.37	Revenue	
ı	(UNAUDITED)	PARTICULARS	
ı	30.9.2013		
31	3	PART 3 Standalone Information	P
ı			
		Remaining unresolved at the end of the quarter	
	2	Disposed of during the quarter	
	2	Received during the quarter	
	<b>₹</b>	Pending at the beginning of the quarter	
	30.9.2013		
	3 MONTHS ENDED	B INVESTOR COMPLAINTS	
			l

			PART 3		
Revenue Profit Before Tax from Ordinary activities Profit After Tax from Ordinary activities Profit After Tax after extraordinary item	PARTICULARS		PART 3 Standalone Information	Remaining unresolved at the end of the quarter	Disposed of during the quarter
7,851.37 1,972.69 1,779.65 1,779.65	(UNAUDITED)	30.9.2013		Z.	2
7,472.47 1,720.79 1,678.83 1,678.83	(UNAUDITED)	30.06.2013	3 MONTHS ENDED		
5,028.81 1,439.82 1,439.82 1,439.82	(UNAUDITED)	30.9.2012			
15,323,83 3,693,47 3,458,47 3,458,47	(UNAUDITED)	30.9.2013	6 MONTHS ENDED		
8,852.08 (533.01) (533.01) (533.01)	(UNAUDITED)	30.9.2012	S ENDED		

- Notes:

  1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31,10,2013.

  2 The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksan's Pharma (LtK.) Limited.

  3 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the institute of Chartered Accountants of India.

  4 The Company is primarily engaged in a single business segment of Marufacturing & Marketing of Pharmaceutical Financial Statement" issued by the institute of Chartered Accountants of India.

  5 The Company will consider the effect of Deferred Tax Assegnition of Pharmaceutical Financial Statement year's figures have been re-grouped/re-classified, whereever necessary, so as to make them comparable with the current year's figures.

40,124.45	43,800.84	ASSETS			_
24 392 61	28 300 56	Sub-total - Current assets	1		_
Ť	•	Other current assets- Miscellaneous expenditure	•		_
1,904.00	980.00	Short-term loans and advances	9		
1,588.00	677.47	Cash and cash equivalents	<u> </u>		
13,131.42	16,203.61	Trade receivables	€		_
7,769.19	10,439.48	Inventories	Đ		
		Current assets		N	
15,731.84	15,500.28	Sub-total - Non-current assets			
120.21	119.25	Long-term loans and advances	<u>e</u>		_
•	•	Non-current investments	ô		_
159.00	159.00	Goodwill on consolidation	ਉ		
15,452.63	15,222.03	Fixed assets	<u>®</u>		
		ASSETS Non-current assets		_	
40,124.45	43,800.84	TOTAL-EQUITY AND LIABILITIES			
29,728.26	30,903.85	Sub-total -Current liabilities		_	
1,869.96	2,797.52	Short-term provisions	<u> </u>		_
10,873.44	9,616.67	Other current liabilities	Ô		
5,606.16	6,419.26	Trade payables	€		_
11,378.70	12,070.40	Short-term borrowings	Đ		_
		Current liabilities		4	
1,049.32	925.15	Sub-total - Non-current liabilities			_
261.64	270.51	Deferred tax liabilities (Net)	ਭ		_
787.68	654.64	Long-term borrowings	9		
		Non-current liabilities		ω	
699.00	609.96	Minority Interest		N	
8,647.87	11,361.88	Sub -total-Shareholders' funds	;		
		Money received against share warrants	<u>o</u>		
3,444.80	6,158.81	Reserves and surplus	€		_
5,203.07	5,203.07	Share capital	◉		
2001	CONTROL	Shareholders' funds		<u></u>	_
Allocation	INALIDATED	EDINTY AND LIABILITIES		1	<b>.</b>
1	30 00 2013 AS at	Particulars			
Turning.			İ	ļ	٦

Place: Mumbai. Date: 31.10.2013 www.marksanspharma.com REMUMBAL-53 PHONE OF THE PROPERTY OF THE PROPE